Myasthenia Gravis

James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains how nerve and muscle signaling in the neuromuscular junction go awry in myasthenia gravis.

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.

The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.

Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

Current myasthenia gravis therapies can exacerbate comorbidities or create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

Results from 2 late-stage trials evaluating generalized myasthenia gravis therapies indicated both drugs, rozanolixizumab and zilucoplan, have potential as targeted treatment options.

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).

A new case series highlights characteristics and challenges of this subgroup of patients with myasthenia gravis (MG).

James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the antibody subtypes associated with this rare neuromuscular disease.

A patient with myasthenia gravis (MG) quickly deteriorated after he woke up from an endovascular procedure.

The new research could help identify ways to preserve neuromuscular junctions.

Female patients were most likely to experience onset of triple-negative myasthenia gravis (MG) between ages 0 to 9 years.

The tool can help clinicians stratify patients into high-risk and low-risk categories.

The patient received a diagnosis of myasthenia gravis (MG), then underwent a medical odyssey as physicians attempted to pin down the cause of his neurological symptoms.

The new report suggests patients with acetylcholine receptor (AChR) antibody titers above 8.11 nmol/L were at higher risk of conversion.

People with muscle-specific kinase myasthenia gravis appear to have more active antibody responses in general, the study found.

The authors said it is the first study of epidemiology and real-world treatment in Germany.

Myasthenia gravis affects about 60,000 individuals in the United States.

Just 26 cases have been reported in which myasthenia gravis (MG) symptoms appeared following vaccination.